AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20535924 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal initial therapy together with Chinese herbal compound (TCM) for clearing heat and detoxification
Number of subjects: 24
Study 20535924 — intervention group
Group type: COMPARATOR
Intervention: Periodontal initial therapy alone (Control group)
Number of subjects: 24
Study 20535924 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 24
Study 17214996 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg (C600)
Number of subjects: 58
Study 17214996 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg (C300)
Number of subjects: 58
Study 15947771 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue velocities (DTV)
Number of subjects: 31
Study 15947771 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial performance index (MPI)
Number of subjects: 31
Study 15947771 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age-matched)
Number of subjects: 31
Study 11819153 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 360 mg/day
Number of subjects: 203
Study 11819153 — intervention group
Group type: COMPARATOR
Intervention: Tacrine up to 160 mg/day
Number of subjects: 203
Study 10566611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy combinations
Number of subjects: 0
Study 10566611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with newer agents (vinorelbine or paclitaxel)
Number of subjects: 0
Study 8948920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone 0.5 mg in gel form (intracervically applied)
Number of subjects: 0
Study 8948920 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PGE2 application)
Number of subjects: 0
Study 2021987 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.08 mg.kg‐1
Number of subjects: 85
Study 2021987 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.15 mg.kg‐1 with perphenazine 2.5‐5.0 mg im
Number of subjects: 85
Study 2021987 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 85
Study 7021431 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiram 50 mg
Number of subjects: 80
Study 7021431 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiram 100 mg
Number of subjects: 80
Study 7021431 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 80
Study 7021431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31347920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga therapy (6 standardized 35-min weekly sessions)
Number of subjects: 70
Study 31347920 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic exercises (CTEs) (6 standardized 35-min weekly sessions)
Number of subjects: 70
Study 31347920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga therapy
Number of subjects: 70
Study 31347920 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic exercises (CTEs)
Number of subjects: 70
Study 28406814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling to 34‐36°C for 48 hours
Number of subjects: 66
Study 28406814 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not cooled)
Number of subjects: 66
Study 26004968 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 56
Study 26004968 — intervention group
Group type: COMPARATOR
Intervention: Foam sclerotherapy
Number of subjects: 56
Study 23192725 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam continuous infusion in hypothermic patients
Number of subjects: 17
Study 23192725 — intervention group
Group type: COMPARATOR
Intervention: Midazolam as sedative in control group
Number of subjects: 17
Study 23192725 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pharmacokinetics between groups
Number of subjects: 17
Study 22042783 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC + G-CSF (5-FU 600 mg/m², doxorubicin 60 mg/m², cyclophosphamide 1000 mg/m² every 18 days for four cycles)
Number of subjects: 202
Study 22042783 — intervention group
Group type: COMPARATOR
Intervention: FAC (5-FU 500 mg/m², doxorubicin 50 mg/m², cyclophosphamide 500 mg/m² every 21 days for four cycles)
Number of subjects: 202
Study 22042783 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC + G-CSF
Number of subjects: 202
Study 22042783 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 202
Study 22042783 — intervention group
Group type: EXPERIMENTAL
Intervention: pCR
Number of subjects: 202
Study 18789432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS: 5.8%)
Number of subjects: 16
Study 18789432 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (IS: 0.9%)
Number of subjects: 16
Study 16004669 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 1085
Study 12361426 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 712
Study 12361426 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 712
Study 10731301 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing in a sulphur pool
Number of subjects: 40
Study 10731301 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing in the Dead Sea
Number of subjects: 40
Study 10731301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sulphur pool and bathing in the Dead Sea
Number of subjects: 40
Study 10731301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no balneotherapy)
Number of subjects: 40
Study 8550130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroxazepine (25 mg PO, HS)
Number of subjects: 0
Study 8550130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1960313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ribose (3.3 mg/kg per min)
Number of subjects: 15
Study 1960313 — intervention group
Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 15
Study 6173512 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment (traditional, stimulus-response type treatment of specific language deficits)
Number of subjects: 0
Study 6173512 — intervention group
Group type: COMPARATOR
Intervention: Group therapy (designed to improve communication through group interaction and discussion, no direct treatment of specific language deficits)
Number of subjects: 0
Study 31662370 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT/sMF before training sessions + PBMT/sMF during detraining
Number of subjects: 0
Study 31662370 — intervention group
Group type: COMPARATOR
Intervention: PBMT/sMF before training sessions + placebo during detraining
Number of subjects: 0
Study 31662370 — intervention group
Group type: COMPARATOR
Intervention: Placebo before training sessions + PBMT/sMF during detraining
Number of subjects: 0
Study 31662370 — intervention group
Group type: COMPARATOR
Intervention: Placebo before training sessions + placebo during detraining
Number of subjects: 0
Study 28803834 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 0
Study 28803834 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 25140032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (group 1) with aerobic exercise program based on verbal and written guidelines
Number of subjects: 34
Study 25140032 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 34
Study 23651130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 12 weeks at 30% of maximal inspiratory pressure (PImax)
Number of subjects: 31
Study 23651130 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) following the same protocol without inspiratory load
Number of subjects: 31
Study 21717887 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise blocked group (earplugs inserted into both ears)
Number of subjects: 58
Study 21717887 — intervention group
Group type: COMPARATOR
Intervention: Control group (earplugs not inserted)
Number of subjects: 58
Study 21717887 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 19439458 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate diet (LC)
Number of subjects: 118
Study 19439458 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric low-fat diet (LF)
Number of subjects: 118
Study 17094121 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (regular coffee)
Number of subjects: 0
Study 17094121 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 0
Study 17094121 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 15678736 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (30 mg kg(‐1)h(‐1)) + Fentanyl (2 microg kg(‐1))
Number of subjects: 40
Study 15678736 — intervention group
Group type: COMPARATOR
Intervention: Propofol (30 mg kg(‐1)h(‐1)) + Normal Saline
Number of subjects: 40
Study 12612777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice with 550 ppm F
Number of subjects: 0
Study 12612777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice with 275 ppm F
Number of subjects: 0
Study 12612777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12612777 — intervention group
Group type: COMPARATOR
Intervention: Crest toothpaste (positive control)
Number of subjects: 0
Study 12612777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice with 1,100 ppm F
Number of subjects: 0
Study 9845405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg (effervescent)
Number of subjects: 20
Study 9845405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg (tablet)
Number of subjects: 20
Study 9845405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg (effervescent)
Number of subjects: 20
Study 9845405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg (tablet)
Number of subjects: 20
Study 9845405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9845405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg (tablet) vs Cimetidine 200 mg (tablet)
Number of subjects: 20
Study 8601521 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to marked MEP in tubes accompanying ovarian LMP tumors
Number of subjects: 191
Study 8601521 — intervention group
Group type: COMPARATOR
Intervention: Normal tubes obtained for sterilization
Number of subjects: 191
Study 8601521 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP presence with ovarian LMP tumors
Number of subjects: 191
Study 8601521 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP presence with benign ovarian lesions, invasive gynecologic cancers, uterine leiomyomas, or tubal inflammatory lesions and ectopic pregnancies
Number of subjects: 191
Study 2569435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose/breath hydrogen method
Number of subjects: 9
Study 2569435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine/sulphapyridine method
Number of subjects: 9
Study 2569435 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of lactulose and sulphazalazine
Number of subjects: 9
Study 2569435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine at 1.5 g and 3.0 g
Number of subjects: 9
Study 134249 — intervention group
Group type: EXPERIMENTAL
Intervention: Volon A40 (one ampoule injected intrathecally and peridurally)
Number of subjects: 160
Study 134249 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical procedure without Volon A40
Number of subjects: 160
Study 31787550 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophins
Number of subjects: 738
Study 31787550 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 738
Study 31240322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 2567
Study 28243685 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 10 mg dimemorfan phosphate tablets
Number of subjects: 24
Study 28243685 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 20 mg dimemorfan phosphate tablets under fed conditions
Number of subjects: 24
Study 28243685 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 40 mg dimemorfan phosphate tablets
Number of subjects: 24
Study 28243685 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dosing of 20 mg dimemorfan phosphate tablets 3 times per day
Number of subjects: 24
Study 28243685 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 20 mg dimemorfan phosphate tablets under fasting conditions
Number of subjects: 24
Study 25512675 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 2 weeks at weeks 0-4; CZP 200 mg every 2 weeks at weeks 6-16
Number of subjects: 41
Study 25512675 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 41
Study 25512675 — intervention group
Group type: COMPARATOR
Intervention: Placebo→CZP (placebo at weeks 0-2; CZP loading dose at weeks 2-6; CZP 200 mg every 2 weeks at weeks 8-16)
Number of subjects: 41
Study 24259595 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Monitoring and Optimization (MeMO) program
Number of subjects: 1002
Study 24259595 — intervention group
Group type: COMPARATOR
Intervention: Usual care (historical reference group)
Number of subjects: 1002
Study 21144679 — intervention group
Group type: COMPARATOR
Intervention: Term infants with perinatal intracerebral hemorrhage (ICH)
Number of subjects: 54
Study 21144679 — intervention group
Group type: COMPARATOR
Intervention: Term infants with perinatal asphyxia
Number of subjects: 54
Study 21144679 — intervention group
Group type: COMPARATOR
Intervention: Preterm infants with ICH
Number of subjects: 54
Study 21144679 — intervention group
Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 54
Study 18053580 — intervention group
Group type: EXPERIMENTAL
Intervention: Light room therapy
Number of subjects: 50
Study 18053580 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 50
Study 16203676 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle nipple with physical characteristics enhancing sucking skills
Number of subjects: 10
Study 12484105 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT) plus relaxation training
Number of subjects: 0
Study 12484105 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 0
Study 9583664 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 28
Study 9583664 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 28
Study 8593994 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright cycling without venous occlusion
Number of subjects: 10
Study 8593994 — intervention group
Group type: COMPARATOR
Intervention: Upright cycling with venous occlusion (bilateral thigh cuffs inflated to 100 mmHg)
Number of subjects: 10
Study 2576667 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, 50 mg/day (Control)
Number of subjects: 143
Study 2576667 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenolol, 60 mg/day
Number of subjects: 143
Study 1269217 — intervention group
Group type: COMPARATOR
Intervention: 0 mg dextroamphetamine
Number of subjects: 12
Study 1269217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dextroamphetamine
Number of subjects: 12
Study 1269217 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dextroamphetamine
Number of subjects: 12
Study 1269217 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg dextroamphetamine
Number of subjects: 12
Study 29309746 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation (10-min duration)
Number of subjects: 63
Study 29309746 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (10-min duration)
Number of subjects: 63
Study 29309746 — intervention group
Group type: COMPARATOR
Intervention: Active stretching (control group, 10-min duration)
Number of subjects: 63
Study 27278101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention delivered by mental health workers
Number of subjects: 13
Study 27278101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention
Number of subjects: 13
Study 27278101 — intervention group
Group type: COMPARATOR
Intervention: Generic stop‐smoking services
Number of subjects: 13
Study 24673076 — intervention group
Group type: EXPERIMENTAL
Intervention: Encephalopathy therapeutic tongue acupoint apparatus (ETTAA) combined with conventional training (behavior training and sensory integration training) for 2 months, apparatus switched on for 20 min, 3 times a day.
Number of subjects: 84
Study 24673076 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (behavior training and sensory integration training) for 2 months.
Number of subjects: 84
Study 20528781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.04% for 3 min)
Number of subjects: 115
Study 20528781 — intervention group
Group type: COMPARATOR
Intervention: Control group with free conjunctival autograft (sutured using 7-0 Vicryl)
Number of subjects: 115
Study 19794135 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily atomoxetine
Number of subjects: 0
Study 19794135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18793579 — intervention group
Group type: COMPARATOR
Intervention: Quantia 200 (generic quetiapine)
Number of subjects: 24
Study 18793579 — intervention group
Group type: COMPARATOR
Intervention: Seroquel (innovator product)
Number of subjects: 24
Study 15960405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg x kg(‐1)
Number of subjects: 90
Study 15960405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg x kg(‐1)
Number of subjects: 90
Study 15960405 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 90
Study 12939113 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 29
Study 12939113 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes (Milrinone and Dobutamine)
Number of subjects: 29
Study 12939113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9849290 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Shao Shang acupoints
Number of subjects: 76
Study 9849290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 76
Study 9849290 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for laryngospasm
Number of subjects: 76
Study 7861798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted quantity-frequency method with questions on occasions with heavy drinking
Number of subjects: 930
Study 2511023 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (Group A, n = 11)
Number of subjects: 23
Study 2511023 — intervention group
Group type: EXPERIMENTAL
Intervention: human proinsulin (Group B, n = 12)
Number of subjects: 23
Study 1233383 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine-imipramine combination
Number of subjects: 24
Study 1233383 — intervention group
Group type: COMPARATOR
Intervention: Thio-thixene placebo
Number of subjects: 24
Study 30703444 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 100 mg moguisteine
Number of subjects: 12
Study 30703444 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg moguisteine
Number of subjects: 12
Study 30703444 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg moguisteine
Number of subjects: 12
Study 30703444 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 200 mg moguisteine (three times daily for five consecutive days)
Number of subjects: 12
Study 30703444 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 30703444 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 12
Study 27130976 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 Hz ablation frequency
Number of subjects: 28
Study 27130976 — intervention group
Group type: COMPARATOR
Intervention: 500 Hz ablation frequency
Number of subjects: 28
Study 25922190 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony stimulating factor (GM‐CSF)
Number of subjects: 280
Study 25922190 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 280
Study 24130357 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made footwear with improved offloading (∼20% peak pressure relief)
Number of subjects: 171
Study 24130357 — intervention group
Group type: COMPARATOR
Intervention: Usual care (nonimproved custom-made footwear)
Number of subjects: 171
Study 24130357 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made footwear with improved offloading (in patients with high adherence)
Number of subjects: 171
Study 24130357 — intervention group
Group type: COMPARATOR
Intervention: Usual care (in patients with high adherence)
Number of subjects: 171
Study 21362469 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h running at 60% V O(2peak) (EX)
Number of subjects: 32
Study 21362469 — intervention group
Group type: COMPARATOR
Intervention: 2 h seated rest (CON)
Number of subjects: 32
Study 19373517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive tobacco‐dependence intervention based on self‐determination theory (SDT)
Number of subjects: 1006
Study 19373517 — intervention group
Group type: COMPARATOR
Intervention: Community care participants received cessation pamphlets and information on local treatment programs
Number of subjects: 1006
Study 16720024 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-defined MetS
Number of subjects: 541
Study 16720024 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS defined by five definitions
Number of subjects: 541
Study 16720024 — intervention group
Group type: COMPARATOR
Intervention: None of the five definitions
Number of subjects: 541
Study 15546073 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 50 mg (1 mg/kg for patients weighing <50 kg)
Number of subjects: 882
Study 15546073 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 400 mg (8 mg/kg for patients weighing <50 kg)
Number of subjects: 882